A case-control study to assess the role of polyomavirus in transplant complications : Where do we stand?
© 2020 Wiley Periodicals LLC..
PURPOSE: The study's aim was to assess whether polyomavirus DNAemia screening was associated with different outcomes in patients with positive viremia compared with negative viremia.
METHODS: Case-control retrospective study of patients with polyomavirus DNAemia (viremia > 1000 copies/mL) matched 1:1 with controls. Control group consists of the patient who received a transplant immediately before or after each identified case and did have nil viremia.
FINDING: Ultimately, 120 cases of BK polyomavirus (BKPyV) were detected and matched with 130 controls. Of these, 54 were adult kidney transplant recipients (KTRs), 43 were pediatric KTRs, and 23 were undergoing hemato-oncologic therapy, of which 20 were undergoing hematopoietic stem cell transplantation. The odds ratio (OR) for overall risk of poorer outcomes in cases versus controls was 16.07 (95% CI: 5.55-46.54). The unfavorable outcome of switching the immunosuppressive drug (ISD) (14/40,35%) was no different from that of those treated with reduced ISD doses (31/71, 43.6%, P = .250). Acute rejection or graft-versus-host disease, previous transplant, and intensity of immunosuppression (4 ISDs plus induction or conditioning) were risk factors for BKPyV-DNAemia (OR: 13.96, 95% CI: 11.25-15.18, P < .001; OR: 6.14, 95% CI: 3.91-8.80, P < .001; OR: 5.53, 95% CI: 3.37-7.30, P < .001, respectively).
CONCLUSIONS: Despite viremia screening, dose reduction, and change in therapeutic protocol, patients with positive BKPyV-DNAemia present poorer outcomes and unfavorable results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 22(2020), 6 vom: 15. Dez., Seite e13432 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
BK polyomavirus |
|---|
| Anmerkungen: |
Date Completed 11.08.2021 Date Revised 11.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.13432 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313142807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313142807 | ||
| 003 | DE-627 | ||
| 005 | 20231225145931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.13432 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313142807 | ||
| 035 | |a (NLM)32738811 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garcia Urbán, Julia |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A case-control study to assess the role of polyomavirus in transplant complications |b Where do we stand? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2021 | ||
| 500 | |a Date Revised 11.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a PURPOSE: The study's aim was to assess whether polyomavirus DNAemia screening was associated with different outcomes in patients with positive viremia compared with negative viremia | ||
| 520 | |a METHODS: Case-control retrospective study of patients with polyomavirus DNAemia (viremia > 1000 copies/mL) matched 1:1 with controls. Control group consists of the patient who received a transplant immediately before or after each identified case and did have nil viremia | ||
| 520 | |a FINDING: Ultimately, 120 cases of BK polyomavirus (BKPyV) were detected and matched with 130 controls. Of these, 54 were adult kidney transplant recipients (KTRs), 43 were pediatric KTRs, and 23 were undergoing hemato-oncologic therapy, of which 20 were undergoing hematopoietic stem cell transplantation. The odds ratio (OR) for overall risk of poorer outcomes in cases versus controls was 16.07 (95% CI: 5.55-46.54). The unfavorable outcome of switching the immunosuppressive drug (ISD) (14/40,35%) was no different from that of those treated with reduced ISD doses (31/71, 43.6%, P = .250). Acute rejection or graft-versus-host disease, previous transplant, and intensity of immunosuppression (4 ISDs plus induction or conditioning) were risk factors for BKPyV-DNAemia (OR: 13.96, 95% CI: 11.25-15.18, P < .001; OR: 6.14, 95% CI: 3.91-8.80, P < .001; OR: 5.53, 95% CI: 3.37-7.30, P < .001, respectively) | ||
| 520 | |a CONCLUSIONS: Despite viremia screening, dose reduction, and change in therapeutic protocol, patients with positive BKPyV-DNAemia present poorer outcomes and unfavorable results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BK polyomavirus | |
| 650 | 4 | |a BKPyV | |
| 650 | 4 | |a hematopoietic cell transplant | |
| 650 | 4 | |a immunosuppressive treatment | |
| 650 | 4 | |a solid organ transplantation | |
| 650 | 4 | |a transplant | |
| 700 | 1 | |a Gurrado, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Brea Rivas, Paola C |e verfasserin |4 aut | |
| 700 | 1 | |a Abou Elrous, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Zubimendi Machain, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Romero Gómez, María |e verfasserin |4 aut | |
| 700 | 1 | |a García Rodríguez, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Vicandi Plaza, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Yébenes Gregorio, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a García Fernández, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez Martín, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a López Oliva, María-Ovidia |e verfasserin |4 aut | |
| 700 | 1 | |a González García, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ledesma Sánchez, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Carreño Cornejo, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Selgas Gutiérrez, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Zarauza Santoveña, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Melgosa Hijosa, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Camblor, Carlota |e verfasserin |4 aut | |
| 700 | 1 | |a Mozo Del Castillo, Yasmina |e verfasserin |4 aut | |
| 700 | 1 | |a Sisinni, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno Sánchez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Martínez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Zapardiel, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a López Granados, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Monserrat Villatoro, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández Zabala, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Borobia, Alberto M |e verfasserin |4 aut | |
| 700 | 1 | |a Frías, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez, Elena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 22(2020), 6 vom: 15. Dez., Seite e13432 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:6 |g day:15 |g month:12 |g pages:e13432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.13432 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 6 |b 15 |c 12 |h e13432 | ||